4DMedical Raises $1.38m Through Underwritten Option Share Issue

The latest update is out from 4DMedical Ltd ( (AU:4DX) ).

4DMedical has issued 834,103 fully paid ordinary shares under an option underwriting agreement with Bell Potter Securities to cover unexercised 4DXO listed options that expired on 31 December 2025, raising approximately $1.38 million before costs at $1.365 per share. The capital raising, conducted without a prospectus under the Corporations Act disclosure exemptions, reinforces the company’s funding position while confirming it remains compliant with its continuous disclosure obligations and has no undisclosed price-sensitive information, providing assurance to investors about governance and transparency as it advances its respiratory imaging technology portfolio.

The most recent analyst rating on (AU:4DX) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited is a global medical technology company focused on revolutionising respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology transforms standard medical scans into detailed functional lung insights, enabling earlier and more precise detection, diagnosis and monitoring of lung disease. The company’s product suite includes FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS and the CT:VQ solution that integrates ventilation and perfusion analysis, all delivered via a Software-as-a-Service model that fits into existing hospital infrastructure. Following its 2023 acquisition of Imbio, 4DMedical has further strengthened its AI capabilities to advance cardiothoracic imaging and personalised respiratory care globally.

Average Trading Volume: 4,682,062

Technical Sentiment Signal: Buy

Current Market Cap: A$2.47B

For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.